Posts By :

admin

Lysogene Reports its Cash Position as of 31 March 2022
Lysogene Reports its Cash Position as of 31 March 2022 150 150 Lysogene

Cash and cash equivalents of €10.7 million[1] as of 31 March 2022 Paris, France —…

Lysogene Publishes Positive Preliminary Preclinical Results in the Treatment of Fragile X Syndrome
Lysogene Publishes Positive Preliminary Preclinical Results in the Treatment of Fragile X Syndrome 150 150 Lysogene

Paris, France — 21 April 2022 at 08:00 am CEST — Lysogene (FR0013233475 – LYS),…

Lysogene Announces Filing of 2021 Universal Registration Document
Lysogene Announces Filing of 2021 Universal Registration Document 150 150 Lysogene

Paris, France — 20 April 2022 at 08:00 am — Lysogene (FR0013233475 – LYS), a…

Lysogene Enters into an Exclusive Worldwide License Agreement with Yeda, the commercial arm of the Weizmann Institute of Science, for a Novel Gene Therapy Candidate for Neuronopathic Gaucher Disease and Parkinson Disease with GBA1 Mutations
Lysogene Enters into an Exclusive Worldwide License Agreement with Yeda, the commercial arm of the Weizmann Institute of Science, for a Novel Gene Therapy Candidate for Neuronopathic Gaucher Disease and Parkinson Disease with GBA1 Mutations 150 150 Lysogene

Lysogene exercises its option after a conclusive research collaboration period Paris, France — 12 April 2022…

Lysogene Reports Full Year 2021 Financial Results
Lysogene Reports Full Year 2021 Financial Results 150 150 Lysogene

Paris, France – 31 March 2022 at 8:00 am CET – Lysogene (FR0013233475 – LYS),…

Lysogene Provides Update on Efficacy, Safety and Timelines of the AAVance phase 2/3 clinical trial with gene therapy LYS-SAF302 for the treatment of MPSIIIA
Lysogene Provides Update on Efficacy, Safety and Timelines of the AAVance phase 2/3 clinical trial with gene therapy LYS-SAF302 for the treatment of MPSIIIA 150 150 Lysogene

Topline data of the main cohort of AAVance clinical trial expected in Q3 2022Stabilization or…

Lysogene Reports Additional Positive Biomarker data with LYS-SAF302 and Favorable Safety data with LYS-GM101 presented at the WORLDSymposium™ 2022
Lysogene Reports Additional Positive Biomarker data with LYS-SAF302 and Favorable Safety data with LYS-GM101 presented at the WORLDSymposium™ 2022 150 150 Lysogene

New positive biomarker data from 16 patients treated with LYS-SAF302 showing reduction in heparan sulfate…

Lysogene Provides Medical Update
Lysogene Provides Medical Update 150 150 Lysogene

Third patient treated in the global clinical trial with LYS-GM101 gene therapy program in GM1…

Lysogene Reports its Cash Position as of 31 December 2021
Lysogene Reports its Cash Position as of 31 December 2021 150 150 Lysogene

Cash and cash equivalents of €12.3 million[1] as of 31 December 2021 Paris, France —…

Lysogene announces termination of license agreement with Sarepta for LYS-SAF302 program, regaining global commercial rights
Lysogene announces termination of license agreement with Sarepta for LYS-SAF302 program, regaining global commercial rights 150 150 Lysogene

Lysogene remains focused on developing its pipeline led by LYS-SAF302, LYS-GM101, Fragile X and other…

Lysogene COVID-19 update

Find out More

Lysogene is developing therapies for children with CNS diseases.

Delivering Gene Therapy’s Promise

About Us
Our Science
Meet the Team
Diseases
Resources

Contact Us
Careers
Transparency
Compassionate Use Policy

©2022 Lysogene. All rights reserved.

Cookie Policy
Privacy Policy
Legal Notice

Get In Touch

Don’t hesitate to contact us if you need more help.

    Start Typing